Intervention,Domain,Score,Evidence,Reference
1. Rapamycin/mTOR Inhibitors,Human Trial Evidence,3,Limited to small-scale studies; FDA-approved for transplant/cancer but early stage for geroscience.,"Mannick JB, et al., 2014, Sci Transl Med, doi:10.1126/scitranslmed.3009892."
1. Rapamycin/mTOR Inhibitors,Safety & Tolerability,3,"FDA-approved but chronic use has moderate risks; high doses cause side effects like metabolic disturbances, stomatitis, and impaired wound healing.","Kaeberlein M, 2014, J Genet Genomics, doi:10.1016/j.jgg.2014.06.009."
1. Rapamycin/mTOR Inhibitors,Preclinical Efficacy (Lifespan),4,"Gold standard evidence; NIA ITP confirmed significant median and maximal lifespan extension (up to 28%) in mice, even when started late in life.","Miller RA, Harrison, et al., 2014, Aging Cell, doi:10.1111/acel.12194."
1. Rapamycin/mTOR Inhibitors,Preclinical Efficacy (Lifespan),4,"Gold standard evidence; NIA ITP confirmed significant median and maximal lifespan extension (up to 28%) in mice, even when started late in life.","Harrison, D. E., et al., 2009, Nature, doi:10.1038/nature08221"
1. Rapamycin/mTOR Inhibitors,Preclinical Efficacy (Healthspan),4,"Broad and potent benefits; delays cognitive decline, cardiac dysfunction, and immune senescence.","Bitto, A., et al., 2016, eLife, doi:10.7554/eLife.16351"
1. Rapamycin/mTOR Inhibitors,Mechanism Conservation,5,"mTOR pathway is a master regulator of metabolism, ubiquitously and highly conserved from yeast to humans.","Saxton RA et al., 2017, Cell, doi:10.1016/j.cell.2017.02.004"
1. Rapamycin/mTOR Inhibitors,Biomarker Availability,3,"Direct, non-invasive biomarker pS6K can be measured in peripheral blood to show target engagement.","Liao, C. et al., 2012, Anticancer Research, PMID: 23060538"
1. Rapamycin/mTOR Inhibitors,Cost & Accessibility,3,Moderate cost as a generic prescription drug.,"Taber, D. J., et al., 2015, Current Opinion in Organ Transplantation, doi:10.1007/s40472-015-0052-y"
2. Metformin,Human Trial Evidence,3,Vast indirect evidence from 60+ years of use; retrospective studies show lower all-cause mortality; prospective TAME trial is pending.,"Barzilai N, et al., 2016, Cell Metab, doi:10.1016/j.cmet.2016.05.011."
2. Metformin,Safety & Tolerability,5,"Unparalleled safety; on WHO Essential Medicines list, used by >150M people. Lactic acidosis is extremely rare.","Flory JH & Lipska K, 2019, JAMA, doi:10.1001/jama.2019.11708."
2. Metformin,Preclinical Efficacy (Lifespan),1,"Inconsistent; extends invertebrate lifespan, but multiple mouse studies (including NIA ITP) failed to show a significant/reproducible effect.","Strong, R., et al., 2016, Aging Cell, doi: 10.1111/acel.12496"
2. Metformin,Preclinical Efficacy (Healthspan),3,"More consistent than lifespan; improves physical performance, insulin sensitivity, and cognitive function in non-human primates.","Kodali, M., et al., 2021, Aging Cell, doi:10.1111/acel.13277"
2. Metformin,Mechanism Conservation,5,"Primary target, AMPK, is an exceptionally conserved central regulator of cellular energy metabolism across all eukaryotes.","Hardie DG, et al., 2012, Nat Rev Mol Cell Biol, doi:10.1038/nrm3368."
2. Metformin,Biomarker Availability,4,"No direct geroscience-specific biomarker; relies on downstream metabolic outcomes (e.g., blood glucose, HbA1c).","Mueller, N. T., et al., 2021, Diabetes Care, doi:10.2337/dc20-2257 "
2. Metformin,Cost & Accessibility,5,Highly accessible; available as a generic drug for pennies a day.,"Soukas AA, et al., 2019, Annu Rev Med, doi:10.1146/annurev-med-050217-054734."
3. Acarbose,Human Trial Evidence,3,Vast evidence from decades of use for diabetes/prediabetes; trials show it can prevent diabetes progression and reduce cardiovascular events.,"DiNicolantonio JJ, et al., 2015, Open Heart, doi:10.1136/openhrt-2015-000327"
3. Acarbose,Safety & Tolerability,3,"Most common side effects are mild, transient GI issues.
Standard dosing of 25-100 mg three times daily with meals causes gastrointestinal side effects, with 74% of patients reporting flatulence in a US trial ","Chiasson J, et al., 2003, JAMA,  doi:10.1001/jama.290.4.486"
3. Acarbose,Safety & Tolerability,3,"Most common side effects are mild, transient GI issues.
Standard dosing of 25-100 mg three times daily with meals causes gastrointestinal side effects, with 74% of patients reporting flatulence in a US trial ","STOP-NIDDM trial., 2003, JAMA, doi:10.1001/jama.290.4.486."
3. Acarbose,Preclinical Efficacy (Lifespan),4,Powerful and rigorously validated; NIA ITP found it extended median lifespan of male mice by 16-22% but 5% in females.,"Harrison DE et al., 2014, Aging Cell, 10.1111/acel.12170"
3. Acarbose,Preclinical Efficacy (Lifespan),4,Powerful and rigorously validated; NIA ITP found it extended median lifespan of male mice by 16-22% but 5% in females.,"Harrison DE et al., 2019, Aging Cell, doi:10.1111/acel.12898"
3. Acarbose,Preclinical Efficacy (Healthspan),4,"Notable benefits in mice including improved metabolic health, diminished liver degeneration, and beneficial modulation of gut microbiota.","Harrison DE et al., 2019, Aging Cell, doi:10.1111/acel.12898"
3. Acarbose,Mechanism Conservation,4,"Primary mechanism (inhibition of alpha-glucosidase) and downstream effects on aging pathways (GLP-1, IGF-I) are highly conserved across mammals.","Harrison DE et al., 2019, Aging Cell, doi:10.1111/acel.12898"
3. Acarbose,Biomarker Availability,4,Clinical effects are easily monitored using standard metabolic biomarkers like blood glucose and HbA1c.,"Holman RR, et al., 2017, The Lancet Diabetes & Endocrinology, doi:10.1016/S2213-8587(17)30309-1"
3. Acarbose,Cost & Accessibility,5,"Highly accessible as a low-cost, widely available generic drug.","DiNicolantonio JJ, et al, 2015, Open Heart, doi:10.1136/openhrt-2015-000327"
4. GLP-1 Receptor Agonists,Human Trial Evidence,4,FDA-approved for diabetes/obesity. Large trials show reduced cardiovascular events. Semaglutide shown to reduce epigenetic age.,"Marso SP, et al., 2016, N Engl J Med, doi:10.1056/NEJMoa1607141"
4. GLP-1 Receptor Agonists,Human Trial Evidence,4,FDA-approved for diabetes/obesity. Large trials show reduced cardiovascular events. Semaglutide shown to reduce epigenetic age.,"Corley MJ, et al., 2024, Nat Commun, doi:10.1038/s41467-024-51772-5."
4. GLP-1 Receptor Agonists,Safety & Tolerability,4,"Well-characterized profile, but side effects like nausea and vomiting can be significant.","Nauck MA, et al., 2021, Lancet, doi:10.1016/S0140-6736(21)00214-7."
4. GLP-1 Receptor Agonists,Preclinical Efficacy (Lifespan),3,"Demonstrates significant benefits for cardiovascular health, neuroprotection, and metabolic function in animal models.","Zheng Z et al., 2024, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-024-01931-z."
4. GLP-1 Receptor Agonists,Preclinical Efficacy (Healthspan),4,"Broad benefits: improved cardiovascular health, reduced hepatic fat, and potential neuroprotective effects.","Somineni HK, 2014, J Endocrinol, doi:10.1530/JOE-13-0532."
4. GLP-1 Receptor Agonists,Mechanism Conservation,4,"Highly conserved pathway in metabolic control (brain, heart, pancreas); mimics endogenous hormone GLP-1."," Drucker DJ, 2018, Cell Metab, doi:10.1016/j.cmet.2018.03.001"
4. GLP-1 Receptor Agonists,Biomarker Availability,4,"Modulates validated epigenetic biomarkers of aging. Metabolic markers (blood glucose, body composition) also available.","Corley MJ, et al., 2025, medRxiv
 [Preprint], doi:10.1101/2025.07.09.25331038."
4. GLP-1 Receptor Agonists,Cost & Accessibility,2,"High cost (~$12,000/year) and inaccessible for many.","Lin T, et al., 2024, Ann Intern Med, doi:10.7326/M23-2736."
5. SGLT2 Inhibitors,Human Trial Evidence,4,"Exceptionally strong evidence; FDA-approved for heart failure and chronic kidney disease, preventing major age-related diseases.","Packer M, et al., 2020, N Engl J Med, doi:10.1056/NEJMoa2024816."
5. SGLT2 Inhibitors,Safety & Tolerability,4,"Excellent profile; side effects (increased urination, genital infections) are manageable and often transient."," Neal B, et al., 2017, N Engl J Med, doi:10.1056/NEJMoa1611925"
5. SGLT2 Inhibitors,Preclinical Efficacy (Lifespan),3,"NIA ITP found a 14% median lifespan extension in male mice, but benefits appear confined to males.","Snyder JM, et al., 2023, Geroscience, doi:10.1007/s11357-022-00641-0."
5. SGLT2 Inhibitors,Preclinical Efficacy (Healthspan),4,"Broad benefits in animal models: reduced visceral fat, preserved lean mass, and mitigation of cardiomyopathy and kidney disease.","Snyder, J.M., et al., 2023, GeroScience, doi:10.1007/s11357-022-00641-0"
5. SGLT2 Inhibitors,Mechanism Conservation,4,"Pleiotropic and highly conserved mechanisms, including modulation of mTOR/AMPK and the NLRP3 inflammasome.","Yesilyurt-Dirican Z et al., 2025, npj Aging and Mechanisms of Disease, doi:10.1038/s41514-025-00227-y"
5. SGLT2 Inhibitors,Biomarker Availability,4,"Reliably reduces inflammatory markers (IL-6) and clinical biomarkers of renal and heart failure (eGFR, NT-pro-BNP).","Yoo TT et al., 2025, Cardiovascular Diabetology, doi:10.1186/s12933-025-02777-7"
5. SGLT2 Inhibitors,Cost & Accessibility,3,Moderate cost as branded prescription drugs.,"Aggarwal R et al., 2022, Circulation: Heart Failure, doi:10.1161/CIRCHEARTFAILURE.121.009099"
6. Alpha-ketoglutarate (AKG),Human Trial Evidence,2,No human trial data for geroscience; a human trial assessing AKG's effect on biological age is in progress.,"Sandalova E et al., 2023, Geroscience, doi:10.1007/s11357-023-00813-6,"
6. Alpha-ketoglutarate (AKG),Safety & Tolerability,4,Considered Generally Recognized as Safe (GRAS) by the FDA; preclinical study in mice found no significant adverse effects.,"Asadi Shahmirzadi A, et al., 2020, Cell Metab, doi:10.1016/j.cmet.2020.08.004."
6. Alpha-ketoglutarate (AKG),Preclinical Efficacy (Lifespan),3,"Consistently extends lifespan in invertebrates; key mouse study showed 12% median lifespan extension, more pronounced in females.","Asadi Shahmirzadi A, et al., 2020, Cell Metab, doi:10.1016/j.cmet.2020.08.004."
6. Alpha-ketoglutarate (AKG),Preclinical Efficacy (Healthspan),3,"Compresses morbidity in aged mice, improving frailty index by over 40% and enhancing physical function.","Asadi Shahmirzadi A, et al., 2020, Cell Metab, doi:10.1016/j.cmet.2020.08.004."
6. Alpha-ketoglutarate (AKG),Mechanism Conservation,4,"Highly conserved as a fundamental metabolite in the TCA cycle, contributing to metabolism, collagen synthesis, and epigenetic regulation.","Wu N et al., 2016, Biomolecules & Therapeutics, doi:10.4062/biomolther.2015.078."
6. Alpha-ketoglutarate (AKG),Biomarker Availability,2,No established geroscience-specific biomarker; plasma AKG levels are not a validated biomarker for its anti-aging effect.,"Sandalova E et al., 2023, Geroscience, doi:10.1007/s11357-023-00813-6."
6. Alpha-ketoglutarate (AKG),Cost & Accessibility,4,Highly accessible; widely available as a low-cost over-the-counter supplement.,"Demidenko O, et al., 2021, Aging (Albany NY), doi:10.18632/aging.203736."
7. Senolytics (D+Q),Human Trial Evidence,3,Preliminary; early-phase trials show reduced senescent cell burden and improved physical function in patients with specific diseases.,"Hickson LJ et al., 2019, EBioMedicine, doi:10.1016/j.ebiom.2019.08.069."
7. Senolytics (D+Q),Safety & Tolerability,3,Key concern as Dasatinib is a powerful chemotherapy drug; long-term effects of intermittent dosing are unknown.,"Rad AN et al., 2024, Current Drug Metabolism, doi:10.1016/j.mad.2023.111888"
7. Senolytics (D+Q),Preclinical Efficacy (Lifespan),3,Positive but modest; pharmacological clearance with D+Q increased median lifespan in mice by ~6.3% in one key study.,"Blagosklonny MV, 2021, Oncotarget, doi:10.18632/oncotarget.28049."
7. Senolytics (D+Q),Preclinical Efficacy (Healthspan),4,"Primary strength; broad and impressive effects, improving cardiovascular function, osteoporosis, physical, and cognitive performance.","Wyatt AW et al., 2021, Annual Review of Pharmacology and Toxicology,  doi:10.1146/annurev-pharmtox-050120-105018"
7. Senolytics (D+Q),Mechanism Conservation,4,Cellular senescence is a highly conserved biological process in vertebrates.,"Davaapil H et al., 2017, Development, doi:10.1242/dev.138222"
7. Senolytics (D+Q),Biomarker Availability,3,"Major barrier; lacks a simple, non-invasive biomarker. Assessment typically requires invasive tissue biopsies (p16INK4a, SA-β-gal).","Muthamil S et al., 2024, Advanced Biology, doi:10.1002/adbi.202400079"
7. Senolytics (D+Q),Cost & Accessibility,2,"Likely to be high cost due to the inclusion of Dasatinib, a chemotherapy drug.","Rad AN et al., 2024, Current Drug Metabolism, doi:10.1016/j.mad.2023.111888"
8. Natural Senolytics (Fisetin),Human Trial Evidence,2,"Early stages; trials are underway for frailty, but no definitive results for an anti-aging indication exist.","Yousefzadeh MJ et al., 2018, eBioMedicine, doi:10.1016/j.ebiom.2018.09.015"
8. Natural Senolytics (Fisetin),Safety & Tolerability,4,"Major advantage; as a natural compound in food, it is generally considered safe for human use.","Yousefzadeh MJ et al., 2018, eBioMedicine, doi:10.1016/j.ebiom.2018.09.015"
8. Natural Senolytics (Fisetin),Preclinical Efficacy (Lifespan),3,"Extended mouse lifespan by ~10% in one study, but contested by NIA ITP testing which found no effect.","Yousefzadeh MJ, et al., 2018, EBioMedicine, doi:10.1016/j.ebiom.2018.09.015."
8. Natural Senolytics (Fisetin),Preclinical Efficacy (Healthspan),3,"Benefits are broad-acting; studies show it can prevent cognitive decline, reduce inflammation, and improve metabolic health in animal models.","Pal HC et al., 2016, Advances in Experimental Medicine and Biology, doi:10.1007/978-3-319-41334-1_10"
8. Natural Senolytics (Fisetin),Mechanism Conservation,4,Acts as a senolytic by clearing senescent cells and inhibiting SASP; also modulates highly conserved PI3K/AKT/mTOR and SIRT1 pathways.,"Tavenier et al., 2024, Mechanisms of Ageing and Development, 10.1016/j.mad.2024.111995"
8. Natural Senolytics (Fisetin),Biomarker Availability,2,"Significant challenge; lacks a simple, non-invasive biomarker for senescent cell burden.","Ogrodnik M et al., 2024, Cell, doi:10.1016/j.cell.2024.05.059"
8. Natural Senolytics (Fisetin),Cost & Accessibility,4,Highly accessible due to low cost and widespread availability as an over-the-counter supplement.,"Yousefzadeh MJ, et al., 2018, EBioMedicine, doi:10.1016/j.ebiom.2018.09.015."
9. NAD+ Restoration (NMN/NR),Human Trial Evidence,3,Growing evidence from small trials confirms safety and efficacy in increasing blood NAD+ levels; reported benefits in muscle insulin sensitivity and walking endurance.,"Yoshino M, et al., 2021, Science, doi:10.1126/science.abe9985."
9. NAD+ Restoration (NMN/NR),Safety & Tolerability,4,Excellent safety profile; multiple human trials found supplements to be safe and well-tolerated with no significant adverse events.,"Berven et al., 2023, Nature Communications, doi:10.1038/s41467-023-43514-6"
9. NAD+ Restoration (NMN/NR),Preclinical Efficacy (Lifespan),3,"NR did not extend lifespan in NIA ITP mouse studies. NMN extended median lifespan by 8.5%, but only in female mice.","Harrison et al., 2021, Aging Cell, doi:10.1111/acel.13328"
9. NAD+ Restoration (NMN/NR),Preclinical Efficacy (Healthspan),3,"Stronger evidence than for lifespan; numerous rodent studies show amelioration of age-associated declines in insulin sensitivity, vascular health, and physical endurance.","Rajman et al., 2018, Cell Metabolism, doi:10.1016/j.cmet.2018.01.008"
9. NAD+ Restoration (NMN/NR),Mechanism Conservation,5,Major strength; NAD+ metabolism is a fundamental and ancient biochemical process conserved across all domains of life.,"Belenky et al., 2007, Trends in Biochemical Sciences"
9. NAD+ Restoration (NMN/NR),Biomarker Availability,4,"The primary goal of boosting NAD+ is a direct, measurable, and non-invasive biomarker via whole blood concentrations.","Martens CR, et al., 2018, Nat Commun, doi:10.1038/s41467-018-03421-7."
9. NAD+ Restoration (NMN/NR),Cost & Accessibility,3,Available as over-the-counter supplements at a moderate cost.,"McDermott et al., 2024, Nature Communications, doi:10.1038/s41467-024-49092-5"
10. Mitochondria (Urolithin A),Human Trial Evidence,3,Promising but preliminary; human trials report positive outcomes in muscle strength and endurance.,"Liu et al., 2022, JAMA Network Open, doi:10.1001/jamanetworkopen.2021.44279"
10. Mitochondria (Urolithin A),Safety & Tolerability,4,Strong safety profile; no serious adverse events reported in human trials.,"Andreux et al., 2019, Nature Metabolism, doi:10.1038/s42255-019-0073-4"
10. Mitochondria (Urolithin A),Preclinical Efficacy (Lifespan),3,Limited but promising; one key study found a 45% increase in lifespan in C. elegans and improved rodent healthspan.,"Ryu et al., 2016, Nature Medicine, doi:10.1038/nm.4132"
10. Mitochondria (Urolithin A),Preclinical Efficacy (Healthspan),4,"Broad benefits including anti-inflammatory, antioxidant, and anti-aging properties; improves muscle function and delays fatigue in animal models.","D’Amico et al., 2021, Trends in Molecular Medicine, doi:10.1016/j.molmed.2021.04.009"
10. Mitochondria (Urolithin A),Mechanism Conservation,4,"Based on activating mitophagy, a highly conserved cellular cleanup process for removing damaged mitochondria.","Faitg et al., 2023, Calcified Tissue International, doi:10.1007/s00223-023-01145-5"
10. Mitochondria (Urolithin A),Biomarker Availability,3,"A challenge; a simple, non-invasive biomarker of its primary effect (mitophagy) is not yet routinely available, but plasma acylcarnitines have been used.","Liu et al., 2022, JAMA Network Open, doi:10.1001/jamanetworkopen.2021.44279"
10. Mitochondria (Urolithin A),Cost & Accessibility,3,"Barrier; branded, clinically-tested formulations are often expensive.","Kuerec et al., 2024, Ageing Research Reviews, doi:10.1016/j.arr.2024.102406"
11. Mitochondria (Elamipretide/SS-31),Human Trial Evidence,2,"Limited to specific rare diseases (e.g., Barth syndrome); primary endpoints have not always been met.","Thompson et al., 2021, Genetics in Medicine, doi:10.1038/s41436-020-01006-8"
11. Mitochondria (Elamipretide/SS-31),Safety & Tolerability,3,"Strength; well-tolerated in trials, with the most common side effects being mild injection-site reactions.","Karaa et al., 2023, Neurology, doi:10.1212/WNL.0000000000207402"
11. Mitochondria (Elamipretide/SS-31),Preclinical Efficacy (Lifespan),2,"Lack of explicit lifespan data, but improves physiological function in aging mouse models.","Chiao et al., 2020, eLife, doi:10.7554/eLife.55513"
11. Mitochondria (Elamipretide/SS-31),Preclinical Efficacy (Healthspan),3,"Strong benefits in preclinical models, including improved cardiac and skeletal muscle function and rescued muscle force in aging mice.","Campbell et al., 2019, Free Radical Biology and Medicine, doi:10.1016/j.freeradbiomed.2018.12.031"
11. Mitochondria (Elamipretide/SS-31),Mechanism Conservation,4,"Highly conserved; targets cardiolipin in the inner mitochondrial membrane to stabilize cristae, reduce oxidative stress, and enhance ATP production.","Szeto, 2014, British Journal of Pharmacology, doi:10.1111/bph.12461"
11. Mitochondria (Elamipretide/SS-31),Biomarker Availability,2,"Functional benefits in mice occurred without detectable changes in epigenetic or transcriptomic age, indicating these clocks do not measure its effect.","Mitchell et al., 2025, Aging Cell, doi:10.1111/acel.70026"
11. Mitochondria (Elamipretide/SS-31),Cost & Accessibility,1,Expected to be prohibitively high as an investigational drug requiring injection.,"Sabbah, 2022, Cardiovascular Drugs and Therapy, doi:10.1007/s10741-021-10177-8"
12. Autophagy Inducers (Spermidine),Human Trial Evidence,2,"Early phases; small studies suggest improved cognitive skills in older adults, but larger trials are needed.","Wirth et al., 2018, Cortex, doi:10.1016/j.cortex.2018.09.014"
12. Autophagy Inducers (Spermidine),Safety & Tolerability,4,Major advantage; excellent safety profile as a natural polyamine found in food; well-tolerated.,"Schwarz et al., 2018, Aging (Albany NY), doi:10.18632/aging.101354"
12. Autophagy Inducers (Spermidine),Preclinical Efficacy (Lifespan),3,"Prolongs lifespan in a wide array of organisms including yeast, flies, worms, and mice.","Eisenberg et al., 2016, Nature Medicine, doi:10.1038/nm.4222"
12. Autophagy Inducers (Spermidine),Preclinical Efficacy (Healthspan),4,"Strong effects, particularly on cardiac and brain function; higher dietary intake correlated with lower incidence of cardiovascular diseases in humans.","LaRocca et al., 2013, Mechanisms of Ageing and Development, doi:10.1016/j.mad.2013.04.004"
12. Autophagy Inducers (Spermidine),Mechanism Conservation,5,"Highly conserved; induces autophagy, a fundamental cellular cleanup process, by inhibiting the acetyltransferase EP300.","Pietrocola et al., 2015, Cell Death & Differentiation, doi:10.1038/cdd.2014.215"
12. Autophagy Inducers (Spermidine),Biomarker Availability,2,"Key challenge; lacks a simple, routine biomarker for measuring autophagy in a clinical setting.","Klionsky et al., 2021, Autophagy (Guidelines, 4th ed.), doi:10.1080/15548627.2020.1797280"
12. Autophagy Inducers (Spermidine),Cost & Accessibility,4,Highly accessible due to low cost and widespread availability as an over-the-counter supplement.,"Madeo et al., 2018, Autophagy Reviews (Perspective), doi: 10.1126/science.aan2788"
13. Chloroquine,Human Trial Evidence,2,"Large body of data from malaria/autoimmune use, but none for a geroscience indication.","Nirk EL et al., 2020, EMBO Molecular Medicine, doi:10.15252/emmm.202012476"
13. Chloroquine,Safety & Tolerability,2,"Major barrier; substantial side effect profile including potential neuromyopathy, retinopathy, and serious heart rhythm problems.","Bansal P et al., 2021, Annals of Medicine, doi:10.1080/07853890.2020.1839959"
13. Chloroquine,Preclinical Efficacy (Lifespan),2,Modest lifespan extension in middle-aged male mice; effects appear to be sex and age-dependent.,"Doeppner TR et al., 2022, Aging (Albany NY), doi:10.18632/aging.204069"
13. Chloroquine,Preclinical Efficacy (Healthspan),2,"Detrimental; emulates aging on the neuromuscular system, causing denervation and decreased muscle force in mice.","Saldarriaga CA et al., 2023, Journal of Applied Physiology, doi:10.1152/japplphysiol.00365.2023"
13. Chloroquine,Mechanism Conservation,4,Conserved across eukaryotes; inhibits autophagy by preventing autophagosome-lysosome fusion.,"Mauthe M et al., 2018, Autophagy, doi:10.1080/15548627.2018.1474314"
13. Chloroquine,Biomarker Availability,2,"No established, non-invasive biomarkers exist for its geroscience effects.","Klionsky DJ et al., 2021, Autophagy (Guidelines), doi:10.1080/15548627.2020.1797280"
13. Chloroquine,Cost & Accessibility,4,"Low cost as a generic drug, but this is irrelevant given its detrimental effects.","Kamat S et al., 2021, Frontiers in Pharmacology, doi:10.3389/fphar.2021.576093"
14. Glutathione Precursors (GlyNAC),Human Trial Evidence,3,"Promising but preliminary; a small, placebo-controlled trial found it was safe and improved a suite of age-associated abnormalities.","Kumar P et al., 2023, Journals of Gerontology Series A, doi:10.1093/gerona/glac135"
14. Glutathione Precursors (GlyNAC),Safety & Tolerability,4,"Human trial reported it was ""safe and well-tolerated"" with ""no adverse events"".","Lizzo G et al., 2022, Frontiers in Aging, doi:10.3389/fragi.2022.852569"
14. Glutathione Precursors (GlyNAC),Preclinical Efficacy (Lifespan),3,"Limited direct studies, but individual components (glycine) have extended lifespan in mice.","Miller RA et al., 2019, Aging Cell, doi:10.1111/acel.12953"
14. Glutathione Precursors (GlyNAC),Preclinical Efficacy (Healthspan),3,"Improves a range of age-related defects in mice (oxidative stress, mitochondrial function, insulin resistance); also improved physical function in a human trial.","Kumar P et al., 2021, Clinical and Translational Medicine, doi:10.1002/ctm2.372"
14. Glutathione Precursors (GlyNAC),Mechanism Conservation,4,Based on a fundamental and highly conserved biochemical process: replenishing glutathione to protect mitochondria from oxidative stress.,"Marí M et al., 2020, Antioxidants, doi:10.3390/antiox9100909"
14. Glutathione Precursors (GlyNAC),Biomarker Availability,3,Major advantage; the primary goal of correcting glutathione deficiency can be reliably quantified in blood and muscle.,"Kumar P et al., 2023, Journals of Gerontology Series A, doi:10.1093/gerona/glac135"
14. Glutathione Precursors (GlyNAC),Cost & Accessibility,4,Highly accessible as a low-cost nutritional supplement.,"Sekhar RV et al., 2022, Antioxidants, doi:10.3390/antiox11010154"
15. Nordihydroguaiaretic Acid (NDGA),Human Trial Evidence,1,Non-existent for a geroscience indication.,"Manda et al., 2020, Frontiers in Pharmacology, doi:10.3389/fphar.2020.00151"
15. Nordihydroguaiaretic Acid (NDGA),Safety & Tolerability,1,Concern; high doses may cause liver and kidney toxicity.,"Lambert et al., 2002, Toxicon, doi:10.1016/S0041-0101(02)00203-9"
15. Nordihydroguaiaretic Acid (NDGA),Preclinical Efficacy (Lifespan),3,"NIA ITP studies showed 8-10% median lifespan extension in male mice, but highly sex-specific with no benefit in females.","Harrison et al., 2014, Aging Cell, doi:10.1111/acel.12170"
15. Nordihydroguaiaretic Acid (NDGA),Preclinical Efficacy (Healthspan),2,Improved neuromuscular performance and physical function in both sexes.,"Tezil et al., 2019, npj Aging and Mechanisms of Disease, doi:10.1038/s41514-019-0037-7"
15. Nordihydroguaiaretic Acid (NDGA),Mechanism Conservation,3,"Based on potent antioxidant/anti-inflammatory properties via conserved pathways (e.g., Nrf2/ARE) in mammals.","Rojo et al., 2012, Free Radical Biology and Medicine, doi:10.1016/j.freeradbiomed.2011.11.003"
15. Nordihydroguaiaretic Acid (NDGA),Biomarker Availability,1,No established biomarkers for its geroscience effects exist in humans.,"Moqri et al., 2023, Cell, doi:10.1016/j.cell.2023.08.003"
15. Nordihydroguaiaretic Acid (NDGA),Cost & Accessibility,2,"Likely inexpensive, but use is limited by safety concerns and lack of human data.","John et al., 2020, Current Cancer Drug Targets, doi:10.2174/1568009619666191022141547"
16. Steroids (17α-estradiol),Human Trial Evidence,1,Non-existent for a longevity intervention.,"Stout et al., 2023, GeroScience, doi:10.1007/s11357-023-00767-9"
16. Steroids (17α-estradiol),Safety & Tolerability,3,Limited safety context from topical use for hair loss; long-term systemic safety in healthy humans is largely unknown.,"Kim et al., 2012, Annals of Dermatology, doi:10.5021/ad.2012.24.3.295"
16. Steroids (17α-estradiol),Preclinical Efficacy (Lifespan),4,19% median lifespan extension in male mice in an NIA ITP study; effect was highly sex-specific.,"Harrison et al., 2021, Aging Cell, doi:10.1111/acel.13328"
16. Steroids (17α-estradiol),Preclinical Efficacy (Healthspan),3,Prevented age-associated sarcopenia and fat gain in male mice without feminizing side effects; improved late-life physical function.,"Garratt et al., 2019, Aging Cell, doi:10.1111/acel.12920"
16. Steroids (17α-estradiol),Mechanism Conservation,4,"Unique non-genomic anti-aging mechanism via membrane estrogen receptors, activating protein kinase cascades and producing epigenetic effects.","Arnal et al., 2017, Physiological Reviews, doi:10.1152/physrev.00024.2016"
16. Steroids (17α-estradiol),Biomarker Availability,2,No established biomarkers for its geroscience effects exist.,"Justice et al., 2018, GeroScience, doi:10.1007/s11357-018-0042-y"
16. Steroids (17α-estradiol),Cost & Accessibility,3,"Likely inexpensive to produce, but would require a prescription and monitoring.","Ramos et al., 2023, Anais Brasileiros de Dermatologia, doi:10.1016/j.abd.2022.09.006"
17. L-deprenyl,Human Trial Evidence,3,Vast indirect evidence from long-term use for Parkinson's disease; no clinical study on healthy human aging.,"Jost WH et al., 2022, Journal of Neural Transmission, doi:10.1007/s00702-022-02465-w"
17. L-deprenyl,Safety & Tolerability,4,Generally well-tolerated at low doses used for Parkinson's; high doses carry risk of interactions.,"Wang K et al., 2023, Frontiers in Aging Neuroscience, doi:10.3389/fnagi.2023.1134472"
17. L-deprenyl,Preclinical Efficacy (Lifespan),4,Meta-analysis of 22 rodent studies showed significant and reproducible lifespan extension.,"Bene MR et al., 2025, Ageing Research Reviews, doi:10.1016/j.arr.2025.102873"
17. L-deprenyl,Preclinical Efficacy (Healthspan),3,Neuroprotective effects; improves aspects of age-related hearing loss in mice; has antioxidant and anti-apoptotic effects.,"Szepesy J et al., 2021, International Journal of Molecular Sciences, doi:10.3390/ijms22062853"
17. L-deprenyl,Mechanism Conservation,4,"Conserved mechanism of irreversible inhibition of monoamine oxidase B (MAO-B), an enzyme in dopamine metabolism.","Tan YY et al., 2022, Journal of Parkinson’s Disease, doi:10.3233/JPD-212976"
17. L-deprenyl,Biomarker Availability,3,"MAO-B activity and dopamine metabolites can be measured, but aging-specific biomarkers are limited.","Justice JN et al., 2018, GeroScience, doi:10.1007/s11357-018-0042-y"
17. L-deprenyl,Cost & Accessibility,4,"Low-cost and widely accessible as an approved, generic drug.","Dorsey ER et al., 2009, Neurology, doi:10.1212/WNL.0b013e3181ae7b04"
18. Epigenetic Reprogramming (OSK),Human Trial Evidence,2,Entirely preclinical; first-in-human trials are beginning for specific indications like vision loss.,"Yücel et al., 2024, Nature Communications, doi:10.1038/s41467-024-46020-5"
18. Epigenetic Reprogramming (OSK),Safety & Tolerability,2,Greatest concern; continuous expression can lead to teratoma formation/cancer; delivery via viral vectors carries risks.,"Abad et al., 2013, Nature, doi:10.1038/nature12586"
18. Epigenetic Reprogramming (OSK),Preclinical Efficacy (Lifespan),5,Most dramatic of all interventions; landmark study showed a 109% extension of remaining median lifespan in very old mice.,"Cano Macip et al., 2024, Cellular Reprogramming, doi:10.1089/cell.2023.0072"
18. Epigenetic Reprogramming (OSK),Preclinical Efficacy (Healthspan),4,Dramatic effects; significant improvement in frailty index and functional rejuvenation in specific tissues.,"Cano Macip et al., 2024, Cellular Reprogramming, doi:10.1089/cell.2023.0072"
18. Epigenetic Reprogramming (OSK),Mechanism Conservation,4,Based on the highly conserved nature of epigenetic regulation across all eukaryotic life.,"Allis et al., 2016, Nature Reviews Genetics, doi:10.1038/nrg.2016.59"
18. Epigenetic Reprogramming (OSK),Biomarker Availability,4,"Strength; DNA methylation-based epigenetic clocks provide a direct, quantitative measure of age reversal.","Horvath et al., 2018, Nature Reviews Genetics, doi:10.1038/s41576-018-0004-3"
18. Epigenetic Reprogramming (OSK),Cost & Accessibility,1,Prohibitively high; current delivery via viral vectors can cost over $1 million per dose.,"Johnson et al., 2023, Nature Biotechnology, doi:10.1038/s41587-023-01760-5"
19. Chemical Reprogramming,Human Trial Evidence,1,No human trial data for geroscience indication.,"Wang J et al., 2023, Cell Stem Cell, doi:10.1016/j.stem.2023.08.001"
19. Chemical Reprogramming,Safety & Tolerability,2,"Unproven for systemic use; small molecules are safer than transgenic methods as they don't integrate into the genome, but systemic use requires thorough testing.","Kim Y et al., 2020, Experimental & Molecular Medicine, doi:10.1038/s12276-020-0383-3"
19. Chemical Reprogramming,Preclinical Efficacy (Lifespan),3,No direct evidence in mammals; one study showed lifespan and healthspan extension in C. elegans.,"Schoenfeldt L et al., 2025, EMBO Molecular Medicine, doi:10.1038/s44321-025-00265-9"
19. Chemical Reprogramming,Preclinical Efficacy (Healthspan),2,"Lacks direct healthspan data for mammalian models, but reverses cellular aging markers in human cells.","Yang JH et al., 2023, Aging (Albany NY), doi:10.18632/aging.204896"
19. Chemical Reprogramming,Mechanism Conservation,4,Strong theoretical basis; targets highly conserved fundamental mechanisms like DNA methylation and histone modification.,"Allis CD et al., 2016, Nature Reviews Genetics, doi:10.1038/nrg.2016.59"
19. Chemical Reprogramming,Biomarker Availability,4,Availability of epigenetic clocks provides a direct and quantitative biomarker for measuring its effects.,"Horvath S et al., 2018, Nature Reviews Genetics, doi:10.1038/s41576-018-0004-3"
19. Chemical Reprogramming,Cost & Accessibility,2,"Likely to be high-cost and require specialist administration, though potentially cheaper than viral vectors.","Kim Y et al., 2020, Experimental & Molecular Medicine, doi:10.1038/s12276-020-0383-3"
20. Immunotherapy for Senescent Cells,Human Trial Evidence,1,"Purely preclinical for geroscience, with no human trials underway.","Lelarge et al., 2024, npj Aging, doi:10.1038/s41514-024-00138-4"
20. Immunotherapy for Senescent Cells,Safety & Tolerability,2,Entirely unknown; risk of off-target effects and autoimmune reactions is a major concern.,"Lelarge et al., 2024, npj Aging, doi:10.1038/s41514-024-00138-4"
20. Immunotherapy for Senescent Cells,Preclinical Efficacy (Lifespan),2,"Preclinical studies show a senolytic CAR-T cell therapy can improve aging phenotypes, but no direct lifespan data is available.","Amor et al., 2024, Nature Aging, doi:10.1038/s43587-023-00560-5"
20. Immunotherapy for Senescent Cells,Preclinical Efficacy (Healthspan),2,Shown to be effective in ameliorating age-associated pathologies like liver fibrosis and metabolic dysfunction in mice.,"Amor et al., 2020, Nature, doi:10.1038/s41586-020-2403-9"
20. Immunotherapy for Senescent Cells,Mechanism Conservation,4,Based on the conserved processes of cellular senescence and the adaptive immune system.,"Ogrodnik et al., 2024, Cell, doi:10.1016/j.cell.2024.05.059"
20. Immunotherapy for Senescent Cells,Biomarker Availability,2,"No simple, non-invasive biomarker exists; assessment requires invasive tissue biopsies.","Ogrodnik et al., 2024, Cell, doi:10.1016/j.cell.2024.05.059"
20. Immunotherapy for Senescent Cells,Cost & Accessibility,1,"Expected to be prohibitively high; similar therapies (CAR T-cell) can cost over $500,000 per dose.","Hernandez et al., 2018, JAMA Oncology, doi:10.1001/jamaoncol.2018.0977"
21. Stem Cell Therapy,Human Trial Evidence,3,"Well-established for hematopoietic disorders, but lacks evidence for a broad anti-aging indication. Some early trials show promise for frailty.","Tompkins et al., 2017, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, doi:10.1093/gerona/glx137"
21. Stem Cell Therapy,Safety & Tolerability,3,"Key consideration; autologous cells reduce rejection risk, but the procedure still carries risks of infection and other complications.","Waszczuk-Gajda et al., 2022, Journal of Clinical Medicine, doi:10.3390/jcm11123541"
21. Stem Cell Therapy,Preclinical Efficacy (Lifespan),2,A study found that transplanting hematopoietic stem cells from young to old mice extended lifespan by ~10%.,"Guderyon et al., 2020, Aging Cell, doi:10.1111/acel.13110"
21. Stem Cell Therapy,Preclinical Efficacy (Healthspan),4,"Broad benefits; can regenerate damaged tissue, modulate the immune system, and reduce inflammation.","Montserrat-Vazquez et al., 2022, npj Regenerative Medicine"
21. Stem Cell Therapy,Mechanism Conservation,4,Highly conserved; stem cells play a fundamental role in tissue repair and regeneration across all complex life forms.,"Bideau et al., 2021, Cellular and Molecular Life Sciences, doi:10.1007/s00018-021-03760-7"
21. Stem Cell Therapy,Biomarker Availability,2,"No single, non-invasive biomarker exists for systemic anti-aging effects; efficacy measured by functional outcomes.","Moqri et al., 2023, Cell, doi:10.1016/j.cell.2023.08.003"
21. Stem Cell Therapy,Cost & Accessibility,1,"Prohibitively high due to specialized collection, processing, and administration.","Preussler et al., 2012, Biology of Blood and Marrow Transplantation (now Transplantation and Cellular Therapy), doi:10.1016/j.bbmt.2012.04.001"
22. Synthetic Tissues/Organs,Human Trial Evidence,2,Field is in its infancy; evidence is limited to specific applications like skin grafts and bladder augmentation.,"Atala et al., 2006, The Lancet, doi:10.1016/S0140-6736(06)68438-9"
22. Synthetic Tissues/Organs,Safety & Tolerability,2,Major concern; involves complex surgery with risks of infection and rejection.,"Kuijer et al., 2007, Biomaterials, doi:10.1016/j.biomaterials.2007.06.003"
22. Synthetic Tissues/Organs,Preclinical Efficacy (Lifespan),2,"Not a preventative intervention; a therapeutic approach to restore function, so lifespan extension is not a direct endpoint.","Mao et al., 2015, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.1508520112"
22. Synthetic Tissues/Organs,Preclinical Efficacy (Healthspan),4,"Potentially immense benefit, as a new organ can restore function completely lost due to disease or aging.","Gallico et al., 1984, The New England Journal of Medicine, doi:10.1056/NEJM198408163110706"
22. Synthetic Tissues/Organs,Mechanism Conservation,3,"Based on fundamental, conserved biological and cellular mechanisms of tissue engineering.","Langer et al., 1993, Science, doi:10.1126/science.8493529"
22. Synthetic Tissues/Organs,Biomarker Availability,3,Function of a new organ can be measured precisely using standard clinical biomarkers.,"McAllister et al., 2009, The Lancet, doi:10.1016/S0140-6736(09)60248-8"
22. Synthetic Tissues/Organs,Cost & Accessibility,1,"Prohibitively high due to complex, custom manufacturing and surgical procedures.","Jessop et al., 2015, Frontiers in Surgery, doi:10.3389/fsurg.2015.00052"
23. Xenotransplantation,Human Trial Evidence,2,Earliest stages; the first successful transplants of genetically modified pig kidneys into living human patients occurred in 2024.,"Kawai et al., 2025, New England Journal of Medicine, doi:10.1056/NEJMoa2412747"
23. Xenotransplantation,Safety & Tolerability,2,"Sizable concerns, including risk of hyperacute rejection and transmission of unknown zoonotic pathogens.","Fishman & Mueller, 2024, Emerging Infectious Diseases, doi:10.3201/eid3007.240273"
23. Xenotransplantation,Preclinical Efficacy (Lifespan),4,"Not a preventative anti-aging intervention, but high potential to extend life by restoring organ function.","Riella, 2025, Journal of the American Society of Nephrology, doi:10.1681/ASN.0000000581"
23. Xenotransplantation,Preclinical Efficacy (Healthspan),4,"Benefit is absolute for a person with a failing organ, potentially saving or extending a person's life.","Kawai et al., 2025, New England Journal of Medicine, doi:10.1056/NEJMoa2412747"
23. Xenotransplantation,Mechanism Conservation,3,"Underlying mechanisms of organ function and immune response are conserved, but significant physiological differences exist between pigs and humans.","Sykes & Sachs, 2022, Nature Reviews Nephrology, doi:10.1038/s41581-022-00624-6"
23. Xenotransplantation,Biomarker Availability,3,Organ function and rejection markers can be monitored using standard transplant protocols.,"Westphal & Mannon, 2025, American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2024.07.018"
23. Xenotransplantation,Cost & Accessibility,1,Prohibitively high; a last-resort procedure requiring lifelong surveillance.,"Anderson & Locke, 2024, Current Transplantation Reports, doi:10.1007/s40472-024-00455-3"
24. Exosome Therapy,Human Trial Evidence,2,Limited and largely focused on aesthetic applications; no large-scale human data for systemic anti-aging effects.,"Gupta et al., 2023, Journal of Cosmetic Dermatology, doi:10.1111/jocd.15869"
24. Exosome Therapy,Safety & Tolerability,3,"Advantage over stem cells as they are acellular, reducing risks like embolism; generally well-tolerated, but long-term systemic safety is unknown.","Xu et al., 2025, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-025-02312-w"
24. Exosome Therapy,Preclinical Efficacy (Lifespan),2,"Limited direct lifespan data, but has regenerative properties with a long-term vision for healthspan and longevity. A recent study reports reports ~12% median lifespan extension in aged mice treated with young plasma sEVs","Chen et al., 2024, Nature Aging, doi:10.1038/s43587-024-00612-4"
24. Exosome Therapy,Preclinical Efficacy (Healthspan),2,"Possess regenerative, immunomodulatory, and anti-inflammatory properties; can stimulate collagen synthesis and promote muscle regeneration.","Sanz-Ros et al., 2022, Science Advances, doi:10.1126/sciadv.abq2226"
24. Exosome Therapy,Mechanism Conservation,3,"Based on intercellular communication, a fundamental and conserved biological process.","Kalluri et al., 2020, Science, doi:10.1126/science.aau6977"
24. Exosome Therapy,Biomarker Availability,2,Efficacy is often measured by downstream functional outcomes and changes in exosome cargo (miRNAs).,"Arora et al., 2025, Scientific Reports, doi:10.1038/s41598-025-15814-y"
24. Exosome Therapy,Cost & Accessibility,2,"Prohibitive cost, making it a highly restricted therapy.","Wang et al., 2024, Clinical and Translational Science, doi:10.1111/cts.13904"
25. Gene Therapy,Human Trial Evidence,1,Entirely preclinical for a geroscience indication.,"Kroemer et al., 2025, Cell, doi:10.1016/j.cell.2025.03.011"
25. Gene Therapy,Safety & Tolerability,2,Most significant barrier; use of viral vectors (AAVs) carries risks of off-target effects and life-threatening immune reactions.,"Ronzitti et al., 2020, Frontiers in Immunology, doi:10.3389/fimmu.2020.00670"
25. Gene Therapy,Preclinical Efficacy (Lifespan),3,Study showed elevating Klotho protein levels via gene therapy extended mouse lifespan by up to 30%.,"Kurosu et al., 2005, Science, doi:10.1126/science.1112766"
25. Gene Therapy,Preclinical Efficacy (Healthspan),3,"Dramatic benefits including improved physical and cognitive function, larger muscle fibers, better bone density, and stimulated neurogenesis.","Roig-Soriano et al., 2025, Molecular Therapy, doi:10.1016/j.ymthe.2025.02.030"
25. Gene Therapy,Mechanism Conservation,4,Based on the fundamental principle of gene regulation; the Klotho gene is a conserved aging-suppressing gene in mammals.,"Xu et al., 2015, Endocrine Reviews, doi:10.1210/er.2013-1079"
25. Gene Therapy,Biomarker Availability,3,"Strength; Klotho protein levels can be directly measured, and its effects on functional and epigenetic markers can be tracked.","Devaraj et al., 2012, American Journal of Clinical Pathology, doi:10.1309/AJCPGPMAF7SFRBO4"
25. Gene Therapy,Cost & Accessibility,1,"Prohibitively inaccessible; among the most expensive medical interventions, with prices in the millions of dollars per dose.","Naddaf, 2022, Nature (news feature), doi:10.1038/d41586-022-04327-7"
26. Telomere Extension Therapies,Human Trial Evidence,2,A gene therapy trial for telomere biology disorders showed sustained telomere elongation without major safety concerns.,"Myers KC et al., 2025, NEJM Evidence, doi:10.1056/EVIDoa2400252"
26. Telomere Extension Therapies,Safety & Tolerability,2,"Primary concern is cancer risk, as uncontrolled telomerase expression can immortalize cells; transient modified RNA technique mitigates this risk.","Ramunas J et al., 2015, FASEB Journal, doi:10.1096/fj.14-259531"
26. Telomere Extension Therapies,Preclinical Efficacy (Lifespan),3,"Modified RNA therapy lengthened telomeres in cultured human cells, allowing them to divide more times.","Ramunas J et al., 2015, FASEB Journal, doi:10.1096/fj.14-259531"
26. Telomere Extension Therapies,Preclinical Efficacy (Healthspan),3,"Modified RNA therapy increased proliferation of cultured human muscle and skin cells, ""turning back the clock"" on a cellular level.","Ramunas J et al., 2015, FASEB Journal, doi:10.1096/fj.14-259531"
26. Telomere Extension Therapies,Mechanism Conservation,4,Based on a fundamental and conserved biological process involving telomeres and telomerase ensuring chromosome integrity.,"Blackburn EH et al., 2006, Nature Medicine, doi:10.1038/nm1006-1133"
26. Telomere Extension Therapies,Biomarker Availability,3,Telomere length itself is a direct and precise biomarker of the intervention's effect.,"Fasching CL, 2018, Critical Reviews in Clinical Laboratory Sciences, doi:10.1080/10408363.2018.1504274"
26. Telomere Extension Therapies,Cost & Accessibility,1,Prohibitively high; early gene therapy trials were exceptionally expensive.,"Naddaf M, 2022, Nature (News Feature), doi:10.1038/d41586-022-04327-7"
27. Gut Microbiome Modulation,Human Trial Evidence,3,Probiotics show moderate effects on immune function in older adults; one pilot trial of a symbiotic reversed biological age.,"Fitzgerald et al., 2021, Aging (Albany NY), doi:10.18632/aging.202913"
27. Gut Microbiome Modulation,Safety & Tolerability,4,Excellent safety for diet-based modulation and many probiotics; FMT carries risks of complications and pathogen transmission.,"DeFilipp et al., 2019, New England Journal of Medicine, doi:10.1056/NEJMoa1910437"
27. Gut Microbiome Modulation,Preclinical Efficacy (Lifespan),3,Fecal microbiota transplantation (FMT) from young to old mice extends lifespan and improves healthspan.,"Bárcena et al., 2019, Nature Medicine, doi:10.1038/s41591-019-0504-5"
27. Gut Microbiome Modulation,Preclinical Efficacy (Healthspan),3,"Can reduce chronic inflammation (""inflammaging""), improve metabolic health, and alleviate depression/anxiety-like behaviors in aged mice.","Parker et al., 2022, Microbiome, doi:10.1186/s40168-022-01243-w"
27. Gut Microbiome Modulation,Mechanism Conservation,4,The interaction between a host and its microbial ecosystem is a highly conserved biological mechanism.,"Wilde et al., 2024, Science, doi:10.1126/science.adi3338"
27. Gut Microbiome Modulation,Biomarker Availability,3,"Microbiota composition can be assessed, but these are not yet standardized biomarkers for routine geroscience trials.","Xu et al., 2024, Microbiome Research Reports, doi:10.20517/mrr.2023.68"
27. Gut Microbiome Modulation,Cost & Accessibility,4,"Lifestyle changes and many probiotics are low-cost; however, therapies like FMT can be very expensive.","Wynn et al., 2023, Cureus, doi:10.7759/cureus.35116"
28. Anti-Inflammatory Therapies,Human Trial Evidence,3,A large trial (ASPREE) found daily low-dose aspirin did not prolong healthy living in older adults and increased bleeding risk.,"McNeil et al., 2018, New England Journal of Medicine, 10.1056/NEJMoa1800722"
28. Anti-Inflammatory Therapies,Safety & Tolerability,3,"Significant risks of side effects, including gastrointestinal bleeding and kidney problems.","Harirforoosh et al., 2013, Journal of Pharmacy & Pharmaceutical Sciences, 10.18433/J3VW2F"
28. Anti-Inflammatory Therapies,Preclinical Efficacy (Lifespan),2,"Conflicting data; one meta-analysis showed lifespan increase, but the NIA ITP study found no increase for aspirin in mice.","Strong et al., 2008, Aging Cell, 10.1111/j.1474-9726.2008.00414.x"
28. Anti-Inflammatory Therapies,Preclinical Efficacy (Healthspan),3,"Reducing inflammation would have broad benefits; drugs like NSAIDs also activate NRF2, a master regulator of cellular homeostasis.","Eisenstein et al., 2022, Immunity, 10.1016/j.immuni.2022.04.015"
28. Anti-Inflammatory Therapies,Mechanism Conservation,4,The inflammatory response is a deeply conserved biological mechanism.,"Medzhitov, 2008, Nature, 10.1038/nature07201"
28. Anti-Inflammatory Therapies,Biomarker Availability,4,"Inflammatory markers like IL-6 and hs-CRP are routinely measured in clinical practice, making it easy to track effects.","Ridker, 2016, Circulation Research, 10.1161/CIRCRESAHA.115.306656"
28. Anti-Inflammatory Therapies,Cost & Accessibility,4,Highly accessible; many drugs are available over-the-counter and are very low cost.,"Grootendorst et al., 2005, Health Services Research, 10.1111/j.1475-6773.2005.00420.x"
29. Young Blood Plasma and Parabiosis,Human Trial Evidence,2,"Very limited; a small trial in Alzheimer's patients showed some functional but no cognitive benefits; FDA cautioned against it as ""unproven"".","Sha et al., 2019, JAMA Neurology, doi:10.1001/jamaneurol.2018.3288"
29. Young Blood Plasma and Parabiosis,Safety & Tolerability,2,"Significant concerns, including the risk of infection and adverse immune reactions.","Pandey et al., 2012, Transfusion, doi:10.1111/j.1537-2995.2012.03663.x"
29. Young Blood Plasma and Parabiosis,Preclinical Efficacy (Lifespan),2,"Lack of specific data on lifespan extension from parabiosis experiments, with some studies showing no benefit.","Yankova et al., 2022, Rejuvenation Research, doi:10.1089/rej.2022.0029"
29. Young Blood Plasma and Parabiosis,Preclinical Efficacy (Healthspan),3,"Early experiments suggested rejuvenation of aged tissues, but later studies showed old blood was more detrimental than young blood was beneficial.","Rebo et al., 2016, Nature Communications, doi:10.1038/ncomms13363"
29. Young Blood Plasma and Parabiosis,Mechanism Conservation,3,Age-related changes in the blood and their effects on tissues are conserved across mammals.,"Lagunas-Rangel, 2024, npj Aging and Mechanisms of Disease, doi:10.1038/s41514-024-00166-0"
29. Young Blood Plasma and Parabiosis,Biomarker Availability,2,Age-related changes in plasma proteins and metabolites have been investigated as potential biomarkers.,"Lehallier et al., 2019, Nature Medicine, doi:10.1038/s41591-019-0673-2"
29. Young Blood Plasma and Parabiosis,Cost & Accessibility,1,Expensive with questionable benefits; limited availability and regulatory restrictions.,"Hofmann, 2018, Transfusion Medicine and Hemotherapy, doi:10.1159/000481828"
30. Plasma Dilution/Apheresis,Human Trial Evidence,3,"A single human trial showed therapeutic plasma exchange (TPE) significantly lowered biological age, providing a powerful proof-of-concept that needs replication.","Kim et al., 2022, GeroScience, 10.1007/s11357-022-00645-w,"
30. Plasma Dilution/Apheresis,Safety & Tolerability,3,TPE is an FDA-approved procedure with a known and generally well-managed safety profile; most side effects are mild-to-moderate.,"Shemin et al., 2007, Journal of Clinical Apheresis, 10.1002/jca.20143"
30. Plasma Dilution/Apheresis,Preclinical Efficacy (Lifespan),2,A preclinical study showed that diluting old plasma was more effective than adding young plasma at rejuvenating multiple tissues in mice.,"Mehdipour et al., 2020, Aging (Albany NY), 10.18632/aging.103418"
30. Plasma Dilution/Apheresis,Preclinical Efficacy (Healthspan),3,"Benefits include rejuvenation of muscle and liver, and promotion of better hippocampal neurogenesis in mice.","Mehdipour et al., 2020, Aging (Albany NY), 10.18632/aging.103418"
30. Plasma Dilution/Apheresis,Mechanism Conservation,4,Based on the conserved concept that aging is driven by an accumulation of detrimental molecular factors in the blood.,"Lagunas-Rangel et al., 2024, npj Aging Mechanisms of Disease, 10.1038/s41514-024-00166-0"
30. Plasma Dilution/Apheresis,Biomarker Availability,3,"Epigenetic clocks provide a direct and quantifiable measure of biological age reversal, used successfully in a human trial.","Fuentealba et al., 2025, Aging Cell, 10.1111/acel.70103"
30. Plasma Dilution/Apheresis,Cost & Accessibility,2,"Significant barrier; cost is high, making it highly inaccessible for broad preventative use.","Winters et al., 2011, BMC Health Services Research, 10.1186/1472-6963-11-101"
